Chronic Kidney Disease Drugs Market 2019 Global Analysis By Key Players Amgen, Teva Pharmaceutical Industries, Pfizer, AstraZeneca Plc, F. Hoffmann-La Roche, Sanofi

Diseases such as diabetes and high blood pressure increase the risk of chronic kidney diseases. According to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. are estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease, which indicates the underlying market potential in chronic kidney disease drugs market. Moreover, according to CDC, high blood pressure and diabetes are leading causes of chronic kidney disease. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. According to the American Diabetes Association (ADA), in 2015, 30.3 million people in the U.S. were suffering from diabetes. According to CDC, in 2014, around 118,000 people in the U.S. started the treatment for end stage renal disease and as more people become aware of this condition, the number of people for treatment will increase. These factors are expected to boost the market growth over the forecast period.

The global chronic kidney disease drugs market was valued at US$ 12,468.2 million in 2017 and is expected to witness a robust CAGR of 3.1% over the forecast period (2018 – 2026).

Request For Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1713

Individual government organizations and manufacturers are working towards increasing the awareness of chronic kidney diseases. For instance, American Kidney Fund (AKF) launched comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). In March 2018, Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Moreover, CVS Health Corporation launched kidney disease initiative in April 2018. In March 2018, Fresenius Medical North America (FMCNA) made a contribution of US$ 40,000 to Kidney School, world’s largest education program for people with chronic kidney disease.

However, delay in the diagnosis of chronic kidney disease is expected to hinder growth of the chronic kidney disease drugs market over the forecast period.

Some major players operating in the chronic kidney disease drugs market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.

Chronic kidney disease (CKD) involves gradual loss of functioning of kidneys. The normal function of kidneys are to filter out and excrete wastes, and excess fluids from the blood are excreted through urine. However, when an individual is suffering from chronic kidney disease, kidneys cannot perform their natural function and wastes, fluids, and electrolytes build up in the body in excess amounts. Signs and symptoms of chronic kidney disease are not apparent until kidney function becomes significantly impaired. The supportive treatment of chronic kidney disease includes delaying the disease progression and kidney damage. Diseases and conditions such as type 1 or type 2 diabetes, high blood pressure, polycystic kidney disease, and recurrent kidney infection leads to chronic kidney disease.

The global chronic kidney disease drugs market is driven by factors such as increasing prevalence of chronic kidney disease and high presence of generic drug manufacturers in the market. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. Individual government organizations and manufactures are indulged in research and development as well as increasing awareness about chronic kidney diseases, which is fostering growth of the chronic kidney disease drugs market. In March 2018, the Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1713

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave

This release was published on openPR.